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Summary Clostridium difficile is a major cause of infectious diarrhea in hospitalized patients.
Many pathogenic strains of Clostridium difficile produce two toxins TcdA and TcdB, both of which
are pro-inflammatory and enterotoxic in human intestine. Clinically relevant toxin A-negative,
toxin B-positive (AB+) strains of Clostridium difficile that cause diarrhea and colitis in humans
have been isolated with increasing frequency worldwide. This perspective describes these
important toxin variant strains and highlights the need to use Clostridium difficile diagnostic
methods that can detect both TcdA and TcdB.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
Clostridium difficile is a common nosocomial pathogen and a
major cause of infectious diarrhea in hospitalized patients.1,2
Colonization with C. difficile is associated with a wide spec-
trum of clinical presentations ranging from asymptomatic
carriage to fulminant pseudomembranous colitis.3 In recent
years the incidence of C. difficile and the number of cases
associated with severe outcomes have increased world-
wide.4—8 This may be related to several factors, including
changing demographics of patients admitted to hospital,
changing infection control policies, or the emergence of
more virulent strains of C. difficile.7,9,10
Two structurally similar toxins denoted as TcdA (308 kDa)
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(CDAD) and most pathogenic strains of C. difficile produce
both toxins (A+B+). Both of these large toxins are glucosyl-
transferases that catalyze the monoglucosylation of threo-
nine 35/37 of small GTP-binding proteins Rho, Rac, and Cdc42
within target cells, and thus modulate several physiological
cellular events resulting in cell death. Structurally these
toxins have three domains: the enzymatic activity is located
in the N terminus of the protein, the middle domain is the
putative translocation region, and the C terminus is involved
in receptor binding. The N termini of TcdA and TcdB demon-
strate 74% homology that accounts for their similar substrate
specificity. The carboxy-terminal domain of both toxins carry
a number of short homologous regions termed combined
repetitive oligopeptides (CROPs).
The role of these toxins in the pathogenesis of CDAD has
been well described.11 Both toxin A and B are proinflamma-
tory, cytotoxic, and enterotoxic in the human colon.12,13
These toxins are encoded by two genes tcdA and tcdB,Published by Elsevier Ltd. All rights reserved.
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Figure 1 Schematic representation of the Clostridium difficile pathogenicity locus of Clostridium difficile 10463 and the alterations
found in the four AB+ strain types described to date. Filled bars represent the repetitive sequences of both toxin genes. All four types
differ in the length of the deletion (indicated by the triangle and open bar) in tcdA and the size of the deletion where known is
indicated. The presence of the 30 end of tcdA in strain XVII has not been confirmed and is therefore indicated with an asterisk.mapping to a 19.6-kb pathogenicity locus (PaLoc) containing
additional regulatory genes.14 C. difficile isolates with
varying genetic modifications within the PaLoc have been
investigated and 28 different toxinotypes have been
described.15,16 These include variant C. difficile that have
deletions, insertions, or polymorphic restriction sites in one
or more of the genes on the PaLoc but which can still produce
functional toxin proteins TcdA and TcdB and toxin-variant
strains (AB+) which fail to produce detectable toxin A15,17
(Figure 1). Toxin variant strains that produce either toxin A or
toxin B are the most commonly isolated variant C. difficile
with modifications in their PaLoc. Until recently, it was
thought that all toxigenic strains associated with disease
produced both TcdA and TcdB. Early studies in animal models
indicated that TcdA and TcdB acted synergistically but that
TcdA was required to produce the initial damage in the
colon.18 Consequently much of the research on the patho-
genesis of CDAD has focused on the inflammation modulated
by toxin A. However many recent reports demonstrate the
clinical importance of A-negative toxin B positive (AB+)
isolates.19—22 Outbreaks of C. difficile diarrhea, sporadic
cases of infection and cases of pseudomembranous colitis
(PMC) caused by AB+ C. difficile have been previously
documented.20,23—25AB+ Clostridium difficile
To date four different AB+ Clostridium difficile strains have
been described and characterized using Rupnik’s toxinotyp-
ing (PCR-RFLP) scheme.15 In the early 1990s two AB+ strain
types were identified that produced TcdB but no detectable
TcdA. Strain 8864, the first toxin variant strain to be char-
acterized, caused hemorrhage, fluid accumulation, and tis-
sue damage in ligated ileal rabbit loops.26,27 Molecularanalysis identified a large deletion of 5.9-kb in the PaLoc
mapping to the 30 end of tcdA and tcdC and which prevented
production of TcdA at a transcriptional level. In addition
there is a 1.1-kb insertion between tcdA and tcdE.28 Tox-
inotyping designates this strain type as toxinotype X15
(Figure 1). Early studies indicated that this strain type pro-
duced a modified form of TcdB29 and subsequent analyses
determined that TcdB-8864 induced a different cytopathic
effect (CPE) compared to TcdB-10463 (TcdB-8864 glucosy-
lates the Rho proteins Rac1, Rap 1/2, and Ral)28 (Figure 2).
Only one organism of strain type 8864 has ever been isolated
(from an asymptomatic adult) and although the clinical
significance of this strain in humans is questionable its viru-
lence in animal models confirms its pathogenic potential.
The second category of AB+ strain types identified were
serogroup F strains (type strain 1470) that were considered
non-pathogenic due to their frequent isolation from asymp-
tomatic infants and their lack of pathogenicity in animal
models.30,31 Like strain 8864 these are also truncated in
the 30 region of the repetitive domain of tcdA. They contain
a 1.8-kb deletion in tcdA, together with a mutation that
introduces a stop codon corresponding to amino acid position
47, leading to the truncation of TcdA-147032 (Figure 1).
Toxinotyping classified these organisms as type VIII. Analysis
of TcdB-1470 indicated that this toxin also has polymorphisms
in its tcdB gene resulting in altered glucosylation and differ-
ential cytopathic effects.33 Sequence analysis of TcdB from
strains 8864 and 1470 showed a high degree of sequence
conservation in the enzymatic domain with substitutions at
only 8 of 560 amino acid positions.28 These novel cytotoxins
are a hybrid between TcdB from reference strain VPI 10463
and Clostridium sordellii lethal toxin (TclS).33 While the
receptor binding domain shares 100% homology with TcdB-
10463 the enzymatic domain is only 79% homologous
(Figure 2). These hybrid toxins suggest that genetic exchange
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Figure 2 Receptor binding domain of variant Clostridium difficile toxin B and toxin B from VPI 10463 demonstrate 99% homology. The
enzymatic domain of variant Clostridium difficile toxin B is only 79% homologous to toxin B from VPI 10463. Variant toxin B glucosylates
different Rho proteins than toxin B from VPI 10463. This is further demonstrated by the differential cytopathic effect on fibroblast cells.and recombination may have occurred between large clos-
tridial toxin (LCT) producing strains of clostridia.
Most recently two additional AB+ strains, toxinotypes XVI
and XVII, have been described.17 Interestingly these newer
toxinotypes contain the genes that code the Clostridium
difficile binary toxin. The molecular mechanism responsible
for the lack of toxin A production in these newer toxinotypes
has not yet been described although these strains also have
deletions in the CROP region of tcdA17 (Figure 1). Although
four AB+ strain types have been described, toxinotype VIII
appears to be the most clinically significant toxin variant
strain type. These have been isolated from four documented
outbreaks, sporadic cases of diarrhea, and cases of pseudo-
membranous colitis. In contrast, only one strain of toxinotype
XVI has been associated with clinical disease and the other
two toxinotypes X and XVII have been isolated from asympto-
matic patients.
Outbreaks of AB+ Clostridium difficile
To date there have been four documented outbreaks asso-
ciated with AB+ Clostridium difficile. The first outbreak
reported in 1998 by Alfa et al. occurred in a Canadian hospital
over a three month period.19,23 There were 16 cases of
nosocomial C. difficile diarrhea on four hospital wards; eight
of the cases spent time on one hospital ward. This outbreak
was associated with a 19% recurrence rate of CDAD and two
deaths. Following the outbreak, the hospital infection con-
trol policy was changed and the laboratory testing for C.
difficile was changed from a toxin A ELISA, which failed to
detect these AB+ strains, to the cell culture cytotoxicity
assay. A second AB+ outbreak occurred in The Netherlands
between 1997 and 1998.20 In this outbreak 24 patients with
AB+ C. difficile were identified. The recurrence rate in thisoutbreak was 13% while there were seven episodes of severe
diarrhea and one death. Clonality of the 16 available out-
break isolates was determined using 16—23S rRNA ribotyping.
This outbreak subsided following a change in the surgical
prophylactic antibiotic policy such that clindamycin was
withdrawn, along with the introduction of strategic infection
control measures. In 2001, 10 patients with identical AB+ C.
difficile strains were identified in a cancer care hospital in
Japan.34 Our group recently described an AB+ C. difficile
outbreak in one Dublin hospital that affected 73 patients
(Drudy et al., submitted for publication). Molecular typing of
90 recovered isolates determined that 95% of the isolates
were AB+ (PCR ribotype 017, toxinotype VIII).
Disease spectrum and transmissibility of
AB+ Clostridium difficile
AB+ Clostridium difficile causes the same spectrum of
disease that is associated with A+B+ strains ranging from
asymptomatic colonization through to the more severe ful-
minant colitis. The rate ofC. difficile recurrence observed in
our study (36%) and other outbreaks due to toxin-variant
strains, is similar to recurrence rates reported by us, and
others, for toxin A+B+ strains. However, outbreaks described
by us and other authors have documented increased disease
severity associated with these AB+ isolates.35 The mechan-
ism(s) responsible for this observed increase in disease
severity are not known. We have previously demonstrated
that the immune response to toxin A was important in
determining clinical presentation and course of CDAD.35,36
Recent in vitro studies have indicated that like TcdA, TcdB is
also a potent enterotoxin capable of inducing 10-fold more
toxicity in human colonic explants than toxin A.13,37 Warny
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A+B+ clones produce 23 times more TcdB and 16 times more
TcdA compared to toxinotype 0 strains.10 Although the
kinetics of toxin B production in AB+ isolates have not
yet been measured these strains do not produce toxin A
and therefore the pathology observed in cases of severe
colitis are likely to result from host inflammatory events
modulated by TcdB. These findings add to an increasing
number of investigations that highlight the importance of
toxin B in the pathogenesis of CDAD.
The mechanisms of nosocomial acquisition, persistence,
and transmission of Clostridium difficile are complex and not
fully understood for all strain types. Other investigators have
determined that greater sporulation and spore germination
capacity along with increased antimicrobial resistance may
contribute to the persistence of A+B+ clonal isolates in the
nosocomial setting.10,38—40 The mechanisms by which AB+
strains persist have not been widely studied. However, the
increased resistance to macrolide, lincosamide and strepto-
gramin (MLS) antibiotics and fluoroquinolones seen in our
outbreak isolates is likely to contribute to persistence in both
the hospital environment and the human gut. Ongoing sur-
veillance at our hospital indicates the persistence of this
strain even though the incidence rate remains low. Surveil-
lance following the outbreak in The Netherlands demon-
strated that their AB+ isolates did not persist. These AB+
strains are no longer found in patients at that institution (E.
Kuiper, personal communication).
Antibiotic resistance in AB+ Clostridium
difficile
An early investigation by Delme´e and Avesani showed that
serogroup F strains (AB+) were usually susceptible to clinda-
mycin and erythromycin.41 Since that time the emergence of
resistance to MLS antibiotics has been documented. Sixteen
AB+ isolates from the outbreak in The Netherlands were
investigated for antibiotic resistance and all were resistant
to clindamycin, erythromycin, and tetracycline and contained
the ermB gene that encoded MLS resistance.20 The isolates
fromtheCanadian and Japanese outbreakswere not tested for
antibiotic susceptibility. The AB+ isolates from our hospital
were also resistant to MLS antibiotics and contained the ermB
gene. In addition ourAB+ strainswere resistant toa number of
newer classes of fluoroquinolones including ciprofloxacin,
ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin. To
our knowledge this is the first description of fluoroquinolone
resistance in this AB+ strain type. Pituch et al. described the
emergence of a clindamycin resistant clone of AB+ C. difficile
isolates in Polish hospitals.42 As C. difficile is not routinely
cultured in many hospital laboratories the true incidence of
antimicrobial resistance among C. difficile is not known. A
current prospective study undertaken by the European C.
difficile study group is investigating antimicrobial resistance
in C. difficile and will generate data with regard to antibiotic
resistance in AB+ and other C. difficile strain types.
Prevalence of AB+ Clostridium difficile
These toxin variant strains have been isolated from several
countries22,43,44 with varying prevalence rates.34,45—47 Forexample, rates of 0.2% have been reported from amulticenter
study in the USA where 2 of 102 Clostridium difficile isolates
from six clinical settings were AB+.47 In the UK prevalence
ratesof 3%havebeendescribed representing 43 isolates from9
of 35 hospitals that submitted strains for typing to the Anae-
robic Reference Laboratory in Cardiff.48 In France, rates of 3%
from 25 different hospitals in Paris were reported.45 In con-
trast,AB+prevalenceratesashighas39%havebeendescribed
in one Japanese study.46 Furthermore, a recent study in Israel
documented AB+ C. difficile rates of 56%.49 A recent study in
Argentina indicated that AB+ strains have completely
replaced A+B+ strains over a four-year time period wherein
AB+ isolates increased from 12.5% in 2000 to 97.9% in 2003.22
Laboratory diagnosis of AB+ Clostridium
difficile
Most laboratory diagnostic tests for Clostridium difficile are
based on either faecal culture or direct toxin detection in
faecal samples. The cell culture cytotoxicity assay is con-
sidered the gold standard for toxin detection and can detect
picogram quantities of toxin after 48 hours. In addition cell
culture can identify these AB+ strains due to the different
CPE induced by these strains as a result of their different
glucosyltransferase substrate specificities. Enzyme immu-
noassays (EIAs) which can detect either TcdA and/or TcdB
are themost commonly used diagnostic approach due to their
ease of use and quick turn-around time although these
methods are less sensitive compared to the cytotoxicity
assay. Toxin A-specific EIAs use antibodies targeted against
the CROP region of tcdA, which is deleted in AB+ strain
types, which therefore fail to react in these assays. A recent
survey carried out by the European Society of Clinical Micro-
biology and Infectious Diseases (ESCMID) study group on C.
difficile determined that among European laboratories per-
forming C. difficile toxin detection, 58% used ELISAs that can
only detect toxin A and therefore toxin AB+ strains would
fail to be detected in these clinical settings.50 Failure to use
standardized C. difficile diagnostic methods that include
both toxin A and B could lead to significant under-reporting
of C. difficile. C. difficile culture lacks specificity due to the
presence of non-toxigenic isolates and takes 48 hours to
complete. However, culture is the only way to type strains
and to test for antimicrobial susceptibility and therefore the
only way in which the emergence and spread of more virulent
or resistant strains can be identified and monitored.
Molecular analysis of AB+ Clostridium
difficile
Several different molecular typing methods have been
applied to AB+ variants including restriction endonuclease
analysis (REA),51 16—23S rRNA ribotyping,52 amplified frag-
ment length polymorphism (AFLP),53 multi-locus sequence
typing (MLST),54 and toxinotyping (PCR-RFLP).15 A recent
study by Lemee et al. applied MLST to 72 C. difficile isolates
from various hosts, geographic locations, PCR ribotypes, and
toxigenic types. The study isolates included eight AB+ iso-
lates from the USA, Japan, and France cultured from human
adults and children. All eight isolates belonged to the same
sequence type and clustered in a very homogenous MLST
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patients. Furthermore, a null allele for one of the seven
housekeeping genes investigated further supported the low
genetic diversity of these AB+ types.54 van den Berg et al.
used AFLP and 16—23S rRNA ribotyping to analyze 39 AB+
strains from seven different countries. AFLP recognized two
genotypes among the 39 isolates while two different ribotyp-
ing methods could differentiate two and three PCR ribotypes,
respectively. All three methods exhibited similar discrimina-
tory power when typing AB+ strain types.53
One international study has compared the relatedness of
23 AB+ strains using three typing methods: serogrouping,
16—23S rRNA PCR ribotyping, and REA.43 This study docu-
mented a high degree of similarity between AB+ strains from
the USA and Europe. Twenty-one of the 23 isolates had a 1.8-
kb deletion in the 30 end of tcdA corresponding to toxinotype
VIII and 20 of the 21 examined were PCR ribotype 017. REA
was the most discriminatory typing method distinguishing 11
REA types among the 23 isolates. This method could further
subtype the 20 PCR 017/serogroup F strains into six different
REA types. PCR ribotyping and serogrouping identified four
and three distinct types respectively. The remaining two
AB+ strains investigated in this international study were
strain 8864, which was unique using all three typing methods.
In addition a PCR ribotype 110/serogroup X/REA DA1 strain
had the same toxin genotype as VPI 10463 but did not produce
any toxin A in vitro.
Concluding remarks
The incidence of AB+ Clostridium difficile strains appears to
be increasing worldwide. These strain types now represent a
substantial number of C. difficile isolates. These isolates may
be under-reported due to the widespread use of diagnostics
that detect TcdA only. Although further studies are required
to determine whether the pathogenesis of toxin variant CDAD
(AB+) differs from that seen with toxin A+B+ strains, clin-
icians should be aware of the risk of severe disease associated
with these variant strain types. TcdB is likely to play a more
prominent role in the pathogenesis of C. difficile than pre-
viously considered, and future work should focus on the
expression and regulation of this toxin as well as modulation
of the host immune response. However the lack of suitable
genetic tools to manipulate C. difficile and lack of isogenic
mutants may hinder progress. New therapeutic approaches
for CDAD such as toxin binders, passive immunotherapy or
active immunization through vaccination will now need to
target both TcdA and TcdB.
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